Академический Документы
Профессиональный Документы
Культура Документы
Q1 2016
Risks
Serious complications may occur in any surgery, including da
Vinci Surgery, up to and including death. Individual surgical
results may vary. Patients should talk to their doctor to
decide if da Vinci Surgery is right for them. Patients and
doctors should review all available information on nonsurgical and surgical options in order to make an informed
decision. Please also refer to
http://www.daVinciSurgery.com/Safety for Important Safety
Information.
Contents Outline
Company Overview & Business
Model
Business Review
Corporate Overview
Founded in 1995, IPO 2000
Over 3 million da Vinci procedures performed to date
Approximately 652,000 da Vinci procedures performed in
2015, up 14% from 2014
$2.38 billion 2015 Revenue, up 12% from 2014
3,597 da Vinci System installed base as of 12/31/15
2,399 United States, 1,198 OUS
$700-$3,200
per procedure
2015 Rev $1,198M
Annual Service
Agreement
da Vinci Surgical System
$0.6M - $2.5M
2015 Rev = $722M
$100K - $170K/Year
2015 Rev = $465M
da Vinci Si-e
$0.6M
Single-Site
$700
Dual Console Xi
Firefly
$2.5M Table Motion
Endowrist
Vessel Sealer
$3,200 Stapler
2015: $138K
da Vinci Si-e
$100K
Dual Console Xi
$170K
Readmissions
Surgical site infections (SSI)
da Vinci Ecosystem
Family of da Vinci Systems
3D HD Imaging,
Fluorescent Imaging
Integrated Energy,
Stapling, Vessel Sealing
Analytics and
Efficiency Programs
BUSINESS REVIEW
2015 Commentary
2015 Objectives
Expanding da Vinci in general
surgery, particularly colorectal
surgery and hernia repair
Filling out our product line for
da Vinci Xi and launching in key
markets globally
Developing our organizational
capabilities and markets in
Europe and Asia
Advancing our technologies to
improve surgery
Lowering our direct product costs
Areas of Strength
General surgery growth
International procedure
growth
da Vinci Xi product line
and feature set
Growing acceptance of
robotic -assisted surgery
Extensive, established
da Vinci ecosystem
Challenges
Structural barriers in
some markets
Single-Site procedures
800,000
2015:
14% Growth
700,000
600,000
500,000
400,000
300,000
200,000
100,000
0
2010
2011
Urology
Company estimates
2012
Gynecology
2013
2014
General Surgery
2015
Other
2016
US Procedure Trend
+11%
500,000
400,000
300,000
200,000
100,000
0
2010
Urology
Company estimates
2011
2012
Gynecology
2013
General Surgery
2014
2015
Other
+26%
140,000
120,000
100,000
80,000
60,000
40,000
20,000
0
2010
2011
Europe
Company estimates
2012
2013
Asia
Rest of World
2014
2015
2015 +14%
140
120
100
80
60
40
20
0
Q1
Q2
Q3
Q4
Q1
2014
U.S.
Q2
Q3
2015
Europe
Asia
Rest-of-World
Q4
2015 +14%
140
120
100
80
60
40
20
0
Q1
Q2
Q3
Q4
Q1
2014
Q2
Q3
2015
Xi
Si
S / Sie
Q4
Total Revenue*
$2,500
2015
70%
Recurring
$2,000
$1,500
$1,000
$500
$0
2010
2011
Systems
2012
Service
2013
2014
Inst & Accy
2015
USA
2,399
Asia
423
Other MIS
Open
Other MIS
Open
Other MIS
Open
Ventral
Hernia
Thoracic
ISI Investments
Advanced imaging
Advanced instrumentation and computerenhanced precision at tissue
Less invasive access
Training technologies
Next generation robotic technologies
International organization
Continued clinical and economic validation
da Vinci Sp
The da Vinci SP is not commercially available. 2016 emphasis will be on clinical investigations
focused on trans oral, trans abdominal, and trans anal procedures.
2016 Priorities
Expand da Vinci in thoracic and general surgery,
particularly colorectal surgery and hernia repair
Advance key technologies extend our product
leadership position
Drive international performance and strengthen
our organization
Maximize total-cost-to-treat value for customers
Corporate Assets
Extraordinary people